CYLD Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5106325-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA5106325 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
CYLD
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CYLD
Gene Alias
2010013M14Rik; 2900009M21Rik; BRSS; C130039D01Rik; CDMT; Cyld; CYLD lysine 63 deubiquitinase; CYLD1; CYLDI; cylindromatosis (turban tumor syndrome); deubiquitinating enzyme CYLD; EAC; FLJ20180; FLJ31664; FLJ78684; HSPC057; KIAA0849; LRRGT00003; MFT; MFT1; mKIAA0849; probable ubiquitin carboxyl-terminal hydrolase CYLD; retinitis pigmentosa 1 homolog; Rp1; Rp1h; SBS; TEM; ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; ubiquitin thioesterase CYLD; ubiquitin thiolesterase CYLD; ubiquitin-specific-processing protease CYLD; Unknown (protein for MGC:137952); USPL2
Host Species
Rabbit
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
1540, 312937, 74256
Content And Storage
-20°C
Form
Liquid
Applications
Immunohistochemistry (Paraffin), Western Blot
Concentration
1 mg/mL
Formulation
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4
Gene Accession No.
Q66H62, Q80TQ2, Q9NQC7
Gene Symbols
CYLD
Immunogen
A synthesized peptide derived from human CYLD(Accession Q9NQC7), corresponding to amino acid residues V876-L926.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Antibody detects endogenous levels of total CYLD
- CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH
- CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway
- CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway
- It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination
- Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.